Arcellx Director Lubner Cashes Out at $115 per Share, Gains $5 CVR in Gilead Merger

*TL;DR: Director David Charles Lubner exited Arcellx with $2.5 million cash and a $108 k contingent right after Gilead’s $115‑per‑share offer.

Context Arcellx (NASDAQ: ACLX) is being acquired by Gilead Sciences (NASDAQ: GILD). The merger agreement, signed Feb. 22, 2026, sets the cash tender price at $115 per share and adds a contingent value right (CVR) that may pay an extra $5 per share if certain milestones are met. The deal values Arcellx at roughly $4.2 billion, a premium of about 30 % over its recent trading range.

Key Facts - Lubner tendered 21,659 common shares into the offer, receiving $115 per share in cash. - Each tendered share also generated one CVR, giving Lubner a potential $5 additional cash payment per share. - All of Lubner’s in‑the‑money stock options—seven tranches totaling 221,000 options with exercise prices below $115—were cancelled. The company paid cash equal to the spread between $115 and each option’s exercise price, plus one CVR per underlying share. - After the cash and CVR allocations, Lubner holds zero Arcellx shares or options. - The cash component totals roughly $2.5 million (21,659 × $115). The CVR component could add up to $108 k if every CVR vests.

What It Means Lubner’s complete exit removes a potential insider influence from Arcellx’s post‑merger governance. The cash‑only settlement of his options reflects the merger’s “cash‑plus‑CVR” structure, which aligns option holders with shareholders by converting intrinsic value into immediate cash and a conditional future payout. For the market, the transaction signals that insiders are satisfied with the $115 price, reinforcing the premium’s credibility. Gilead’s acquisition, now at a market cap of about $4.2 billion, positions it to expand its cell‑based therapy pipeline.

Looking Ahead Investors will watch the CVR trigger events and Gilead’s integration progress, which will determine whether the $5 per CVR adds material value to the deal.